Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Financial Year ended 31st March 2026

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI LODR

Date of Board Meeting / Approval: Commenced on 21st August 2026 at 23:16 hours, concluded on 22nd August 2026 at 00:25 hours.

Audit Opinion: Unmodified Opinion (Clean)

Auditor’s Comment: The revision corrects inadvertent errors identified subsequent to the original issuance of results on 7th May 2026. The audit procedures were carried out solely on the matter of revision with no additional procedures for other events post 7th May 2026.

Key Financial Highlights [Unit: ₹ million]

Standalone Results:

For the Year Ended 31-Mar-2026 (Revised Audited):

  • Revenue from Operations: ₹12,988.14 (Previously reported FY25: ₹9,580.61)
  • Total Income: ₹13,120.57
  • Net Profit: ₹849.31
  • EPS: ₹14.84
  • Other Equity: ₹8,306.68

For the Quarter Ended 31-Mar-2026 (Revised Audited):

  • Revenue from Operations: ₹3,582.77
  • Total Income: ₹3,609.57
  • Net Profit: ₹224.01
  • EPS: ₹3.91

Consolidated Results:

For the Year Ended 31-Mar-2026 (Revised Audited):

  • Revenue from Operations: ₹16,300.18 (Previously reported FY25: ₹12,436.76)
  • Total Income: ₹16,374.38
  • Net Profit: ₹1,431.83
  • EPS: ₹25.02
  • Other Equity: ₹10,242.89

For the Quarter Ended 31-Mar-2026 (Revised Audited):

  • Revenue from Operations: ₹4,478.02
  • Total Income: ₹4,493.66
  • Net Profit: ₹403.49
  • EPS: ₹7.05

Debt (Consolidated):

  • Non-current borrowings: ₹2,148.02 million
  • Current borrowings: ₹1,278.67 million
  • Total Borrowings: ₹3,426.69 million

Cash and Cash Equivalents (Consolidated): ₹31.99 million

Segment-wise Performance:

The Group has only one reportable segment: "Drugs and pharmaceutical products" as per Ind-AS 108.

Corporate Actions:

An interim dividend of ₹2 per equity share (face value ₹10) was approved by the Board on 23rd January 2026.

Other Significant Information:

Brownfield Expansion Approval:

  • The Board approved the brownfield expansion of the existing manufacturing facility at 81-B, EPIP Phase-I, Jharmajri, Baddi, Himachal Pradesh.
  • Existing Capacity: 2 Oral Solid Dosage lines, 1 Ointment line (~85-90% utilization).
  • Proposed Addition: 2 new Oral Solid Dosage production lines.
  • Investment: ₹45 crore.
  • Timeline: Expected completion in 18-22 months.
  • Mode of Financing: Combination of bank credit and internal accruals.
  • Rationale: To increase production capacity, improve operational efficiency, optimize costs, and support long-term growth.

New Labour Codes: The Group has accounted for liabilities related to gratuity and leave encashment following the effective date of the New Labour Codes (21 November 2025) and continues to monitor regulatory developments.

Entities in Consolidation: Innova Captab Limited (Holding Co.), Univentis Medicare Ltd (Subsidiary), Sharon Bio-Medicine Ltd (Step-Down Subsidiary), Univentis Foundation (Subsidiary).